Spark Therapeutics Company Profile (NASDAQ:ONCE)

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

Spark Therapeutics, Inc. (NASDAQ:ONCE) posted its earnings results on Wednesday, August, 2nd. The company reported ($1.89) EPS for the quarter, missing analysts' consensus estimates of ($1.75) by $0.14. The firm had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The firm's revenue was up 14.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.04) earnings per share. View Spark Therapeutics' Earnings History.

12 analysts have issued 1-year target prices for Spark Therapeutics' stock. Their predictions range from $28.00 to $100.00. On average, they expect Spark Therapeutics' stock price to reach $84.55 in the next year. View Analyst Ratings for Spark Therapeutics.

Here are some recent quotes from research analysts about Spark Therapeutics stock:

• 1. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (8/5/2017)
• 2. Chardan Capital analysts commented, "We continue to expect ENDP shares to be range-bound in the near to medium term. Our recent analysis of ENDP’s additional unfunded mesh liability and discussion with a legal expert familiar with mass tort/product liability defense ligation supports our view ENDP will remain highly levered (in the 4s) and the company’s turnaround will take several years. While we view any of our potential settlement scenarios for the company’s additional unfunded mesh liability to be manageable, we believe continued pricing pressure in ENDP’s US generics base business, need for additional advertising and promotion spend to support Xiaflex growth and inability to grow through meaningful acquisitions leave ENDP little room for error." (7/24/2017)
• 3. Cantor Fitzgerald analysts commented, "2017 – Year of First Gene Therapy Approval in U.S.? Management reiterated its confidence in filing its rolling BLA in early 2017, and highlighted that the company has completed the necessary manufacturing runs to support its submission. Outstanding items for the filing include finalization of stability testing and CMC module write-up. We believe the timing of the filing could lead to the first approved gene therapy in the U.S. this year and remind investors that the FDA previously amended its granted orphan designation for voretigene neparvovec to cover inherited retinal diseases caused by biallelic RPE65 mutations." (2/23/2017)
• 4. Stifel Nicolaus analysts commented, "Management's 4Q16 earnings announcement/call contained minimally-incremental insight on many of the data catalysts still anticipated for 1H17. We believe management's commentary around the current state of pre-commercialization activities for voretigene neparvovec (VN) ' including directionally positive feedback on both the access and reimbursement fronts ' should ameliorate some of the near-term concerns of those investors anticipating pricing/reimbursement to potentially represent a source of headline risk. We believe anticipation around a number of key near-term data catalysts ' including early-FY17 SPK-7001 data in choroideremia, updated early-April SPK-9001 data in hemophilia B, and preliminary mid-FY17 SPK-8011 data ' should keep ONCE shares at the forefront of relevancy over the coming months. Estimates largely unchanged." (2/23/2017)

Some companies that are related to Spark Therapeutics include Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Clovis Oncology (CLVS), AveXis (AVXS), Juno Therapeutics (JUNO), Agios Pharmaceuticals (AGIO), BeiGene (BGNE), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Sarepta Therapeutics (SRPT), Axovant Sciences (AXON), Loxo Oncology (LOXO), Prothena Corporation PLC (PRTA), Aerie Pharmaceuticals (AERI), NovoCure Limited (NVCR) and Halozyme Therapeutics (HALO).

Spark Therapeutics' management team includes the folowing people:

• Steven M. Altschuler M.D., Independent Chairman of the Board
• Katherine A. High M.D., President, Chief Scientific Officer, Director
• Jeffrey D. Marrazzo, Chief Executive Officer, Co-Founder, Director
• Stephen W. Webster, Chief Financial Officer
• John Furey, Chief Operating Officer
• Joseph W. La Barge Esq., General Counsel
• Daniel R. Faga, Chief Business Officer
• Lars G. Ekman M.D., Ph.D., Independent Director
• Anand Mehra M.D., Independent Director
• Vincent J. Milano, Independent Director

(ONCE) raised $88 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Spark Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include TYPENEX COMPANY -INVESTMENT, LLC (9.99%), FMR LLC (15.07%), BlackRock Inc. (6.63%), Vanguard Group Inc. (6.21%), JPMorgan Chase & Co. (5.19%) and Federated Investors Inc. PA (4.38%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High, Stephen W Webster and Steven Altschuler. View Institutional Ownership Trends for Spark Therapeutics.

Spark Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., PointState Capital LP, Capital World Investors, State Street Corp, Wells Fargo & Company MN, Ameriprise Financial Inc., Fred Alger Management Inc. and AXA. Company insiders that have sold Spark Therapeutics stock in the last year include Anand Mehra, Barge Joseph La, Daniel Faga, Jeffrey D Marrazzo, Katherine A High and Stephen W Webster. View Insider Buying and Selling for Spark Therapeutics.

Spark Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., Sectoral Asset Management Inc, Vanguard Group Inc., JPMorgan Chase & Co., Citigroup Inc., Northern Trust Corp and Quantitative Investment Management LLC. View Insider Buying and Selling for Spark Therapeutics.

Shares of Spark Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Spark Therapeutics stock can currently be purchased for approximately $74.80.